Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Similar documents
Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

2018 ICD-O-3 Updates in Table Format with Annotation for Reference

2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:

Summary NAACCR: What you need to know for 2017 Version 1.1. March ICD-O-3 Histologies. Reportability There are no reportability changes in 2017.

S2199 S2200. * Speaker's diagnosis 78

2018 Updates to National Standards

Appendix 4: WHO Classification of Tumours of the pancreas 17

ICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31

Contents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology

2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING

incidence rate x 100,000/year

CODING TUMOUR MORPHOLOGY. Otto Visser

Rare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD

Lung Tumor Cases: Common Problems and Helpful Hints

* Speaker's diagnosis

Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology

BMaP-3 Cancer Database. Aggregate Data File

Vulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact

S Y M P O S I U M P R O G R A M

Supplementary Information

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #

Differential Diagnosis of Oral Masses. Palatal Lesions

GUIDELINES FOR ICD-O-3 UPDATE IMPLEMENTATION Effective January 1, 2014

Methoden / Methods inc. ICCC-3 105

Protocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast

Normal endometrium: A, proliferative. B, secretory.

Surveys and Anatomic Pathology Education Programs

FINALIZED SEER SINQ QUESTIONS

Minimally invasive adenocarcinoma. 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS)

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction

Pathology Mystery and Surprise

What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP

SUPPLEMENTARY INFORMATION

List of Available TMAs in the PRN

Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry

2007 Multiple Primary and

Spindle Cell Lesions Of The Breast. Emad Rakha Professor of Breast Pathology and Consultant Pathologist

Neoplasias Quisticas del Páncreas

Surveys and Anatomic Pathology Education Programs

North American Association of Central Cancer Registries, Inc. (NAACCR) What You Need to Know for Version 1.1

CURRICULUM FOR THE BREAST PATHOLOGY ROTATION UNIVERSITY OF FLORIDA DEPARTMENT OF PATHOLOGY

Appendix E SEER Program Coding and Staging Manual DRAFT Reportable Examples

SHN-1 Human Digestive Panel Test results

Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1

Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases

Rare cancers are those with an incidence rate 6/100,000

CANCER REGISTRY 2002

04/09/2018. Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances

Salivary Glands 3/7/2017

S2326. Paucicellular myxoid liposarcoma 1 Histiocytic sarcoma 1 Alveolar soft part sarcoma 1 Perivascular epithelioid cell tumor (PEComa) 1

The European Commission s science and knowledge service. Joint Research Centre

Diagnostically Challenging Cases in Gynecologic Pathology

Layer Tumour Rate Patients 1 EPITHELIAL TUMOURS OF THE NASAL CAVITY and SINUSES Squamous cell carcinoma and variants of the Nasal Cavity

Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency

Gross appearance of peritoneal cysts. They have a thin, translucent wall and contain a clear fluid.

VULVAR CARCINOMA. Page 1 of 5

57th Annual HSCP Spring Symposium 4/16/2016

SUPPLEMENTARY INFORMATION

Enterprise Interest None

Detailed Table of Contents

ANNUAL CANCER REGISTRY REPORT-2015

WHO 2017: New Classification of Head and Neck Tumours

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS

ANNUAL CANCER REGISTRY REPORT-2016, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN

of 20 to 80 and subsequently declines [2].

Pancreatic Cytopathology: The Solid Neoplasms

Recent advances in breast cancers

FINALIZED SEER SINQ QUESTIONS

Molecular pathology in soft tissue tumors. Sylvia Höller Pathologie

Case year female. Routine Pap smear

Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies

Molecular Diagnostics of Head and Neck Tumors Justin A. Bishop, M.D. Associate Professor of Pathology The Johns Hopkins University Baltimore, Maryland

INDEX. in this web service Cambridge University Press

Financial disclosures

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

Papillary Lesions of the breast

Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013

Breast pathology. 2nd Department of Pathology Semmelweis University

FINALIZED SEER SINQ QUESTIONS

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Index. J Juvenile hyaline fibromatosis, 27 Juvenile xanthogranuloma, 57 Juxta-articular myxoma, 152

Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual

LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR

Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node

ANNUAL CANCER REGISTRY REPORT-2017, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

ICD-O-3 UPDATES - PENDING

Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement

ICD-O-3 UPDATES - PENDING

Diagnostic IHC in lung and pleura pathology

CANCER REGISTRY 2004

EQA Circulation 43 Educational Cases

Update in Salivary Gland Pathology. Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016

Ludvik R. Donner, MD, PhD Reference List

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted

Carcinoma of unknown primary origin (CUP) is defined

Transcription:

Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9) 8023/3 Midline carcinoma of children and young adults with NUT rearrangement (C30.0, C31.9, C34. _) 8023/3 NUT carcinoma (C30.0, C31.9, C34. _) 8023/3 NUT midline (C30.0, C31.9, C34. _) 8041/3 High grade neuroendocrine carcinoma (C54. _, C55.9) 8041/3 Neuroendocrine carcinoma, poorly differentiated (C50. _) 8041/3 Small cell carcinoma pulmonary type (C56.9) 8044/3 Small cell carcinoma, hypercalcemic type (C56.9) 8054/3 Condylomatous carcinoma (C60.0 C60.2, C60.9) Cases diagnosed prior to 1/1/2018 use code 8051/3 All other sites use 8051/3 2018 forward 8054/3 Warty carcinoma (C60.0 C60.2, C60.9) Cases diagnosed prior to 1/1/2018 use code 8051/3 All other sites use 8051/3 2018 forward 8071/2 Differentiated penile intraepithelial neoplasia (C60. _) N Not reportable for 2018 8071/2 Differentiated type vulvar intraepithelial neoplasia (C51. _) N Not reportable for 2018 8085/3 Squamous cell carcinoma, HPV positive (C01.9, C10.2, C10.3, C10.8, C10.9, C31.0 C31.3, C31.9)

8086/3 Squamous cell carcinoma, HPV negative (C01.9, C10.2, C10.3, C10.8, C10.9, C31.0 C31.3, C31.9) 8120/3 Clear cell (glycogen rich) urothelial carcinoma (C65.9, C66.9, C67. _, C68. _) /N 8120/3 Lipid rich urothelial carcinoma (C65.9, C66.9, C67. _, C68. _) 8120/3 Microcystic urothelial carcinoma (C65.9, C66.9, C67. _, C68. _) 8120/3 Nested urothelial carcinoma (C65.9, C66.9, C67. _, C68. _) 8120/3 Squamotransitional cell carcinoma (C53. _) 8120/3 Urothelial carcinoma with divergent differentiation (C65.9, C66.9, C67. _, C68. _) 8120/3 Urothelial carcinoma with squamous differentiation (C65.9, C66.9, C67. _, C68. _) 8120/3 Urothelial carcinoma with trophoblastic differentiation (C65.9, C66.9, C67. _, C68. _) 8140/3 Minimally invasive adenocarcinoma, NOS (C34. _) 8140/3 Acinar adenocarcinoma (C61.9 ONL) For prostate only, do not use 8550/3 8140/3 Endocervical adenocarcinoma usual type (C53. _) 8144/3 Enteric adenocarcinoma (C34.0, C67. _, C65.9, C66.9, C68. _) 8144/3 Intestinal type adenocarcinoma (C30.0, C53. _) 8144/3 Mucinous carcinoma, intestinal type (C53. _) 8158/1 ACTH producing tumor N 8158/1 Endocrine tumor, functioning, NOS N 8163/3 Adenocarcinoma, pancreatobiliary type (C24.1) Cases diagnosed prior to 1/1/2018 use code 8255/3 8163/3 Pancreatobiliary type carcinoma (C24.1) Cases diagnosed prior to 1/1/2018 use code 8255/3

/N 8200/3 Thymic carcinoma with adenoid cystic carcinoma like features (C37.9) 8213/3 Serrated adenocarcinoma (C18.0, C18.2, C18.9, C19.9, C20.9) 8246/3 Neuroendocrine tumor, well differentiated (C50. _) 8250/2 Adenocarcinoma in situ, non mucinous (C34. _) 8250/3 Lepidic adenocarcinoma (C34. _) 8250/3 Lepidic predominant adenocarcinoma (C34. _) 8253/2 Adenocarcinoma in situ, mucinous (C34. _) Important note: lung primaries ONL: For cases diagnosed 1/1/2018 forward do not use code 8480 (mucinous adenocarcinoma) for insitu adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. 8253/3 Invasive mucinous adenocarcinoma (C34. _) Important note: lung primaries ONL: For cases diagnosed 1/1/2018 forward do not use code 8480 (mucinous adenocarcinoma) for insitu adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. 8254/3 Mixed invasive mucinous and non mucinous adenocarcinoma (C34. _)

/N 8256/3 Minimally invasive adenocarcinoma, non mucinous (C34. _) 8257/3 Minimally invasive adenocarcinoma, mucinous (C34. _) 8263/3 Endometrioid adenocarcinoma, villoglandular (C54. _, C55.9) 8263/3 Villoglandular carcinoma (C53. _) 8265/3 Micropapillary adenocarcinoma (C34. _) Cases diagnosed prior to 1/1/2018 use code 8507/3. 8265 is not valid for C50._. Use 8507 for micropapillary adenocarcinoma in breast primaries 8265/3 Micropapillary carcinoma, NOS (C18. _, C19.9, C20.9, C34. _) Cases diagnosed prior to 1/1/2018 use code 8507/3. 8265 is not valid for C50._. Use 8507 for micropapillary adenocarcinoma in breast primaries 8311/3 Hereditary leiomyomatosis & RCC associated renal cell carcinoma (C64.9) 8311/3 MiT family translocation renal cell carcinoma (C64.9) 8312/3 Renal cell carcinoma, unclassified (C64.9) 8316/3 Acquired cystic disease associated renal cell carcinoma (RCC) (C64.9) 8316/3 Tubulocystic renal cell carcinoma (C64.9) 8339/3 Follicular thyroid carcinoma (FTC), encapsulated angioinvasive (C73.9)

/N 8343/2 Non invasive EFVPTC (C73.9) Cases diagnosed 1/1/2017 forward 8343/2 Non invasive encapsulated follicular variant of papillary thyroid carcinoma (non invasive EFVPTC) (C73.9) Cases diagnosed 1/1/2017 forward 8343/2 Non invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP) (C73.9) Cases diagnosed 1/1/2017 forward 8343/2 Non invasive FTP (C73.9) Cases diagnosed 1/1/2017 forward 8343/3 Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS) (C73.9) Cases diagnosed 1/1/2017 forward 8343/3 Invasive encapsulated follicular variant of papillary thyroid carcinoma Cases diagnosed 1/1/2017 forward (invasive EFVPTC) (C73.9) 8380/2 Atypical hyperplasia/endometrioid intraepithelial neoplasm (C54. _, N Not reportable for 2018 C55.9) 8441/2 Serous endometrial intraepithelial carcinoma (C54. _, C55.9) 8441/2 Serous tubal intraepithelial carcinoma (C57.0) 8453/2 Intraductal papillary mucinous neoplasm with high grade dysplasia (C25. _) 8453/3 Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma (C25. _) 8460/2 Non invasive low grade serous carcinoma (C56.9) 8460/2 Serous borderline tumor micropapillary variant (C56.9) N Not reportable for 2018 8460/3 Low grade serous carcinoma (C48. _, C56.9, C57.0, C57.1 C57.3) 8461/3 High grade serous carcinoma (C48. _, C56.9, C57.0, C57.1 C57.3)

/N 8470/3 Mucinous cystic tumor with associated invasive carcinoma (C25. _) 8474/3 Seromucinous carcinoma (C56.9) 8480/1 Low grade appendiceal mucinous neoplasm (C18.1) N 8480/3 Mucinous tubular and spindle cell carcinoma (C64.9) 8482/3 Mucinous carcinoma, gastric type (C53. _) 8500/2 Low grade cribriform cystadenocarcinoma (LGCCC) (C06.9, C08.9) 8500/2 Mammary carcinoma, in situ (C50. _) 8500/2 Non invasive mammary carcinoma (C50. _) 8500/3 Invasive carcinoma of no special type (C50. _) 8500/3 Invasive carcinoma, NST (C50. _) 8500/3 Invasive mammary carcinoma (C50. _) 8500/3 Salivary duct carcinoma (C06.9, C08.9) 8503/2 Intraductal papilloma with ductal carcinoma in situ (C50. _) 8503/2 Intraductal tubulopapillary neoplasm (C25. _) 8503/3 Intracystic papillary neoplasm with associated invasive carcinoma 8504/2 Encapsulated papillary carcinoma (C50. _) 8504/3 Encapsulated papillary carcinoma with invasion (C50. _) 8507/3 Invasive micropapillary carcinoma (C50. _) For sites other than C50. _, see 8265/3 8509/2 Solid papillary carcinoma in situ (C50. _) 8509/3 Solid papillary carcinoma with invasion (C50. _) 8510/3 Renal medullary carcinoma (C64.9) 8519/2 Pleomorphic lobular carcinoma in situ (C50. _) rule F DOES NOT APPL to code 8519. Invasive pleomorphic

/N lobular carcinoma is coded 8520/3 8520/2 Intraductal papilloma with lobular carcinoma in situ (C50. _) 8520/3 Invasive lobular carcinoma (C50. _) 8520/3 Invasive lobular carcinoma, alveolar type (C50. _) 8520/3 Invasive lobular carcinoma, solid type (C50. _) 8520/3 Invasive lobular carcinoma, tubulolobular variant (C50. _) 8520/3 Pleomorphic lobular carcinoma (C50. _) 8520/3 Tubulolobular carcinoma (C50. _) 8550/3 Acinar cell carcinoma Excludes C61.9 see 8140/3 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3 8552/3 Mixed acinar ductal carcinoma Cases diagnosed prior to 1/1/2018 use code 8523/3 8570/3 Endometrioid carcinoma with squamous differentiation (C54. _, C55.9) 8570/3 Low grade adenosquamous carcinoma (C50. _) 8571/3 Carcinoma with chondroid differentiation (C50. _) 8571/3 Carcinoma with osseous differentiation (C50. _) 8571/3 Metaplastic carcinoma with chondroid differentiation (C50. _) 8571/3 Metaplastic carcinoma with osseous differentiation (C50. _) 8572/3 Acinar adenocarcinoma, sarcomatoid (C61.9) 8572/3 Fibromatosis like metaplastic carcinoma (C50. _) 8574/3 Adenocarcinoma admixed with neuroendocrine carcinoma (C53. _) 8575/3 Carcinoma with other types mesenchymal differentiation (C50. _)

/N 8575/3 Metaplastic carcinoma of no special type (C50. _) 8575/3 Metaplastic carcinoma with other types mesenchymal differentiation (C50. _) 8594/1 Mixed germ cell sex cord stromal tumor, unclassified (C48.2, C56.9, N C57.9) 8620/3 Adult granulosa cell tumor (C56.9 ONL) N Not reportable for 2018 cases 8714/3 Malignant perivascular epithelial cell tumor 8714/3 PEComa, malignant 8714/3 Perivascular epithelioid cell tumor, malignant 8720/3 Meningeal melanoma (C70. _, C71._) 8801/3 Undifferentiated spindle cell sarcoma 8802/3 Undifferentiated pleomorphic sarcoma 8803/3 Undifferentiated round cell sarcoma 8804/3 Undifferentiated epithelioid sarcoma 8805/3 Undifferentiated uterine sarcoma 8811/1 Myxoinflammatory fibroblastic sarcoma (MIFS) (C49. _) N 8815/0 Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS) (C71. _) for CNS code/ 8815/1 Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS) (C71. _) for CNS ONL 8815/3 Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS) (C71. _) 8825/3 Low grade myofibroblastic sarcoma (C01.9, C02. _, C06.9, C49._) 8825/3 Myofibroblastic sarcoma

/N 8830/3 Malignant fibrous histiocytoma (MFH) of bone 8830/3 Undifferentiated high grade pleomorphic sarcoma 8832/3 Fibrosarcomatous dermatofibrosarcoma protuberans 8840/3 Low grade fibromyxoid sarcoma 8840/3 Sclerosing epithelioid fibrosarcoma 8842/3 Ossifying fibromyxoid tumor, malignant (C49. _) 8842/3 Pulmonary myxoid sarcoma with EWSR1 CREB1 translocation (C34. _) 8912/3 Sclerosing rhabdomyosarcoma 8933/3 Mullerian adenosarcoma (C54. _, C55.9) 8975/1 Calcifying nested epithelial stromal tumor (C22.0) N 8983/3 Adenomyoepithelioma with carcinoma (C50. _) 8990/3 Phosphaturic mesenchymal tumor, malignant 9020/3 Periductal stromal tumor, low grade (C50. _) 9045/3 Biphenotypic sinonasal sarcoma (C30.0, C31.0 C31.3, C31.8, C31.9) 9086/3 Germ cell tumors with associated hematological malignancy (C37.9) 9110/3 Adenocarcinoma of rete ovarii (C56.9) 9133/3 Epithelioid hemangioendothelioma 9137/3 Intimal sarcoma 9137/3 Pulmonary artery intimal sarcoma 9187/3 Low grade central osteosarcoma (C40. _, C41._) 9187/3 Low grade intramedullary osteosarcoma (C40. _, C41._)

/N 9220/3 Chondrosarcoma grade II/III (grade 2/3) 9302/3 Ghost cell odontogenic carcinoma (C41.0, C41.1) 9341/3 Clear cell odontogenic carcinoma (C41.0, C41.1) 9382/3 Anaplastic oligoastrocytoma (C71. _) 9382/3 Oligoastrocytoma, NOS (C71. _) 9385/3 Diffuse midline glioma, H3 K27M mutant (C71._) 9395/3 Papillary tumor of pineal region (C75.3) Cases diagnosed prior to 1/1/2018 use code 9361/3 9396/3 Ependymoma, RELA fusion positive (C71. _) 9400/3 Diffuse astrocytoma, IDH mutant (C71. _) 9400/3 Diffuse astrocytoma, IDH wildtype (C71. _) 9401/3 Anaplastic astrocytoma, IDH mutant (C71. _) 9401/3 Anaplastic astrocytoma, IDH wildtype (C71. _) 9424/3 Anaplastic pleomorphic xanthroastrocytoma (C71. _) 9425/3 Pilomyxoid astrocytoma (C71._) Cases diagnosed prior to 1/1/2018 use code 9421/3 9431/1 Angiocentric glioma (C71._) Cases diagnosed prior to 1/1/2018 use code 9380/1 9432/1 Pituicytoma (C75.1) Cases diagnosed prior to 1/1/2018 use code 9380/1 9440/3 Epithelioid glioblastoma (C71._) 9440/3 Glioblastoma, IDH wildtype (C71._) 9445/3 Glioblastoma, IDH mutant (C71._) 9450/3 Oligodendroglioma, IDH mutant and 1p/19q codeleted (C71._)

9451/3 Anaplastic oligodendroglioma, IDH mutant and 1p/19q codeleted (C71. _) /N 9470/3 Medulloblastoma, classic 9471/3 Medulloblastoma, SHH activated and TP53 wildtype (C71. _) 9475/3 Medulloblastoma, WNT activated (C71. _) 9476/3 Medulloblastoma, SHH activated and TP53 mutant (C71. _) 9477/3 Medulloblastoma, group 3 (C71. _) 9477/3 Medulloblastoma, group 4 (C71. _) 9477/3 Medulloblastoma, non WNT/non SHH (C71. _) 9478/3 Embryonal tumor with multilayered rosettes C19MC altered (C71. _) 9478/3 Embryonal tumor with multilayered rosettes, NOS (C71. _) 9508/3 CNS Embryonal tumor with rhabdoid features (C71. _) 9508/3 Embryonal tumor with rhabdoid features (C71._) 9509/1 Diffuse leptomeningeal glioneuronal tumor (C71. _) 9509/1 Papillary glioneuronal tumor (C71. _) Cases diagnosed prior to 1/1/2018 use code 9505/1 9509/1 Rosette forming glioneuronal tumor (C71. _) 9542/3 Epithelioid malignant peripheral nerve sheath tumor (C47.0 C47.6, C47.8, C47.9) 9560/1 Melanotic schwannoma (C72.4, C72.5)

/N 9741/1 Indolent systemic mastocytosis N